STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G/A] PolyPid Ltd. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Rosalind Advisors, related individuals and a fund report collective beneficial ownership of 5,762,349 common shares of PolyPid Ltd., representing 9.9% of the outstanding common stock based on 15,897,201 shares outstanding per the issuer's disclosure. The reported position consists of 975,462 shares of Common Stock and 4,786,887 shares issuable upon exercise of warrants.

The filings show shared voting and dispositive power over 5,762,349 shares and no sole voting or dispositive power. The warrants include a blocker provision that prevents exercise to the extent it would increase beneficial ownership above 9.99%, and the filing states actual ownership after giving effect to those blockers is less than the amounts reported.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: A concentrated 9.9% position is disclosed, largely warrant-based, with blocker limits reducing immediate economic/control impact.

Rosalind Advisors, its named principals and Rosalind Master Fund L.P. report an aggregate 5,762,349-share position in PolyPid (PYPD). The position is materially composed of 4,786,887 warrant-linked shares, with only 975,462 shares as direct common stock. The presence of a blocker that prevents exercise above 9.99% is critical: it limits conversion risk and near-term dilution from warrant exercises. Shared voting/dispositive power indicates coordinated ownership among the reporting persons rather than independent, sole-control stakes.

TL;DR: Disclosure is comprehensive but the blocker and disclaimers reduce clarity on actual exercisable influence.

The Schedule 13G/A provides required transparency by quantifying both owned shares and warrant exposure. However, the filing also states the advisor and portfolio managers disclaim beneficial ownership of the shares held by the fund, and the blocker restricts warrant exercise above 9.99%. For governance analysis, the combination of shared powers, substantial warrant holdings and explicit disclaimers means stakeholder influence is limited and conditional, not an outright controlling position.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: This percentage is calculated based upon 15,897,201 Ordinary shares of the Issuers common stock outstanding as of July 27, 2025, based on the issuers F-3 Filing of July 29, 2025. However, as more fully described in Item 4, the securities reported in rows 6, 8 and 9 show the number of shares of Common Stock that would be issuable upon full conversion and exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows 6, 8 and 9. (6) 975,462 shares of Common Stock 4,786,887 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G




Comment for Type of Reporting Person: (6) 975,462 shares of Common Stock 4,786,887 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G




Comment for Type of Reporting Person: (6) 975,462 shares of Common Stock 4,786,887 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G




Comment for Type of Reporting Person: (6) 975,462 shares of Common Stock 4,786,887 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G



Rosalind Advisors, Inc.
Signature:Steven Salamon
Name/Title:President
Date:08/13/2025
SALAMON STEVEN A J
Signature:Steven Salamon
Name/Title:Steven Salamon
Date:08/13/2025
Aharon Gil
Signature:Gil Aharon
Name/Title:Gil Aharon
Date:08/13/2025
Rosalind Master Fund L.P.
Signature:Mike McDonald
Name/Title:Director, Rosalind (Cayman) Ltd. (as General Partner to Rosalind Master Fund)
Date:08/13/2025
Polypid Ltd.

NASDAQ:PYPD

PYPD Rankings

PYPD Latest News

PYPD Latest SEC Filings

PYPD Stock Data

59.46M
12.51M
16.7%
41.2%
0.22%
Biotechnology
Healthcare
Link
Israel
Petah Tikva